10-hydroxynortriptyline and Heart-Diseases

10-hydroxynortriptyline has been researched along with Heart-Diseases* in 1 studies

Other Studies

1 other study(ies) available for 10-hydroxynortriptyline and Heart-Diseases

ArticleYear
Comparative cardiotoxicity of nortriptyline and its isomeric 10-hydroxymetabolites.
    Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology, 1992, Volume: 6, Issue:1

    The potential cardiotoxicity of the hydroxymetabolites of nortriptyline (NT) has been raised by inferential data from clinical studies and by the experimentally demonstrated cardiac effects of 2-OH-imipramine. Cardiac output, arterial pressure, and a continuous electrocardiogram were assessed after intravenous de novo administration of NT or its hydroxymetabolites to 41 swine. NT at doses ranging from 3.5 to 7 mg base per kilogram caused significantly more arrhythmias than did E-10-hydroxynortriptyline (E-10-OH-NT) but was not significantly different from Z-10-hydroxynortriptyline (Z-10-OH-NT) in this effect. Z-10-OH-NT, in contrast, to its geometrical isomer caused marked bradycardia, and decrements in blood pressure and cardiac output. NT and Z-10-OH-NT, but not E-10-OH-NT, produced dose-correlated declines in cardiac output. The hydroxymetabolites had smaller volumes of distribution, shorter half-lives and larger free fractions compared with NT. The differing cardiotoxicity of the hydroxymetabolites could not be accounted for by differing pharmacokinetic properties.

    Topics: Animals; Arrhythmias, Cardiac; Blood Pressure; Blood Proteins; Cardiac Output, Low; Chromatography, High Pressure Liquid; Dialysis; Electrocardiography; Half-Life; Heart Diseases; Isomerism; Nortriptyline; Protein Binding; Swine

1992